

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

NCT07002398

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	VeonGen Therapeutics GmbH
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (6)

- To be eligible for study entry, subjects must satisfy all the following criteria:
- Written informed consent.
- Subjects aged e 6 years.
- Clinical diagnosis of a macular lesion phenotypically consistent with a recessive hereditary macular dystrophy (Stargardt disease).
- Confirmed molecular diagnosis of ABCA4 mutations (homozygotes or compound heterozygotes).
- ... and 1 more (see full listing online)

Exclusion (7)

- Subjects will be excluded from the study if one or more of the following statements are applicable to either eye:
- Pre-existing eye conditions such as uveitis, glaucoma, or diabetic retinopathy or implantation of a medical device in the vitreous cavity or subretinal space.
- Systemic diseases that would preclude the planned surgery or interfere with the interpretation of study results.
- History of intraocular surgery within the previous 6 months.
- Previous participation in a gene therapy trial.
- ... and 2 more (see full listing online)

Locations (1 total)

Shanghai General Hospital, Shanghai, Shanghai Municipality, China